SCHEMBL3374148

SCHEMBL3374148

CCOC(=O)C(=Cc1ccc(OCc2ccccc2)c2ccccc12)OCC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 1/20 0.49
CCR8 P51685 1/20 0.44
ALDH1A1 P00352 3/20 0.44
MRGPRX4 Q96LA9 1/20 0.44
LMNA P02545 4/20 0.42
KDM4E B2RXH2 1/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
MAPT P10636 4/20 0.41
L3MBTL1 Q9Y468 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
HPGD P15428 2/20 0.40
ALOX12 P18054 1/20 0.40
NTSR1 P30989 1/20 0.40
CCR6 P51684 1/20 0.40
MCL1 Q07820 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3374141 1.00 NR1H4 (0.49) NR1H4CCR8ALDH1A1MRGPRX4LMNA
SCHEMBL27506711 0.85 NR1H4 (0.53) NR1H4ALDH1A1MRGPRX4LMNAKDM4E
SCHEMBL3369872 0.85 NR1H4 (0.44) NR1H4ALDH1A1LMNAKDM4EMEN1
SCHEMBL3372227 0.85 NR1H4 (0.44) NR1H4CCR8ALDH1A1LMNAKDM4E
SCHEMBL3372221 0.85 NR1H4 (0.44) NR1H4CCR8ALDH1A1LMNAKDM4E
SCHEMBL3370910 0.85 NR1H4 (0.44) NR1H4CCR8ALDH1A1LMNAKDM4E
SCHEMBL5761948 0.83 MRGPRX4 (0.48) ALDH1A1MRGPRX4LMNAKDM4EMAPT
SCHEMBL3371640 0.82 RXRA (0.49) NR1H4ALDH1A1LMNAKDM4EFFAR4
SCHEMBL3370253 0.79 NR1H4 (0.56) NR1H4ALDH1A1LMNAKDM4EMEN1
SCHEMBL5017432 0.79 NR1H4 (0.58) NR1H4ALDH1A1MRGPRX4LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1537091-B1 NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMMA AGONISTS HOFFMANN LA ROCHE (CH) 2010-10-06 EP disclosed
EP-1392295-B1 CARBOXYLIC ACID SUBSTITUTED OXAZOLE DERIVATIVES FOR USE AS PPAR-ALPHA AND -GAMMA ACTIVATORS IN THE TREATMENT OF DIABETES HOFFMANN LA ROCHE (CH) 2006-05-31 EP disclosed
US-6809110-B2 NONINSULIN DEPENDENT DIABETES; SUCH AS 2-ETHOXY-3-(4-(2-(5-METHYL-2-PHENYL-THIAZOL-4-YL)-ETHOXY)-BENZO(B)THIOPHEN-7-YL)-PROPIONIC ACID HOFFMANN-LA ROCHE INC. 2004-10-26 US disclosed
US-20040110807-A1 Thiazole derivatives HOFFMANN-LA ROCHE INC. 2004-06-10 US disclosed
US-6642389-B2 For therapy of diabetes HOFFMANN-LA ROCHE INC. 2003-11-04 US disclosed
US-20030055265-A1 Oxazole derivatives HOFFMANN-LA ROCHE INC. 2003-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110807-A1 Thiazole derivatives SLC5A1, GPR119, INSR NR1H4 512/4885CCR8 2452/4885ALDH1A1 274/4885
US-20030055265-A1 Oxazole derivatives PPARD, PPARA, PPARG NR1H4 81/4885CCR8 2042/4885ALDH1A1 827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.